7/27/2021Understanding "Internet Plus Healthcare" in China: Policy Text Analysi...

7/23/2021Novartis Reports Strong H1 & Q2 Global and China Performance

7/23/2021Roche Reports Flat H1 Performance with Moderate China Drug Sales Growt...

7/23/2021Menarini AP Acquires China Rights of Cialis (Tadalafil) from Lilly

7/23/2021Recent Executive Moves

7/22/2021Aptamer and WuXi AppTec Collaborate to Identify New Optimer Enabled Th...

7/22/2021Merck and Adagene Ink Trial Collaboration and Supply Agreement for Com...

7/22/2021Mabpharm/Sorrento Granted Chinese Approval for Infliximab Biobetter

7/22/2021Ascletis Granted Chinese Approval of PIII Trial of ASC40 Combo with B...

7/20/2021South Korea's Medipost Drops Joint Venture Plan in China

7/20/2021Eluminex Bio Licenses FibroGen's Biosynthetic Cornea Technology and Re...

7/20/2021Review of Chinese Pharma Deals, R&D and Regulatory Developments in H1/...

7/19/2021Junshi Bio and Immorna Announce JV for mRNA-based Therapeutics and Va...

7/16/2021NHSA Issues the BMI Management Procedures for Disease Group-based Diag...

7/16/2021Recent Executive Moves

7/16/2021Chinese Premier Calls for More Efforts to Enhance BMI Access, Budget M...

7/15/2021Kintor Pharma Ties Up with Fosun for Covid-19 Treatment Proxalutamide ...

7/15/2021HUTCHMED's MAA for Surufatinib Validated by the European Medicines Age...

7/14/2021Innovent and Ascentage Reach Strategic Deal for Olverembatinib in Chin...

7/14/2021Teva's NDA for Copaxone Injection Accepted by the Chinese CDE

7/14/2021AstraZeneca Granted Chinese Approval for New SCLC Indication of Imfinz...

7/13/2021New Report: Global and Chinese CDMO Markets to Rise 11.2% and 19.9% CA...

7/13/2021Kintor Pharma Greenlighted for Pyrilutamide's Phase II Trial in the US

7/13/2021Takeda's NSCLC Drug Mobocertinib NDA Accepted with Priority Review in ...

7/13/2021PharmaDJ's China Market Approval Tracker: May 2021

7/13/2021Nikkei: Avigan Maker Fujifilm Faces Patent Risk from China's AMMS

7/13/2021Seizing Opportunities in China's Healthcare Sector

7/11/2021Shanghai I-Mab  Enters Two New Oncology Partnerships

7/9/2021MOFCOM Plans to Beef Up Scrutinization of Foreign Investment

7/9/2021Takeda's NDA for Mobocertinib (TAK-788) Accepted in China as a Treatme...

Page:96/367 Total number of articles:10986: [First][<<] [94] [95] [96] [97] [98] [>>] [End]